Updated March 29, 2020

Patients with a substance use disorder (SUD), mental illness or chronic pain are among those who may be acutely affected by interruptions in medical care, including interruptions in access to medications used as part of their treatment regimen. As the COVID-19 pandemic continues to challenge our health care system, the AMA encourages providers to use the information below as guidance to help ensure continuity of care for their patients.

Featured updates: COVID-19

Track the evolving situation with the AMA's library of the most up-to-date resources from JAMA, CDC and WHO.


The National Institute on Drug Abuse has alerted the research community that populations with Substance Use Disorders (SUDs) may be impacted particularly hard and details implications.

In response to the COVID-19 pandemic, SAMHSA is offering several resources for mental and substance use disorder treatment providers and others. Included among the SAMHSA resources are:

American Association for the Treatment of Opioid Dependence has prepared a guidance for OTPs which includes useful information related to maintaining medication supply, facility infectious disease control standards, protecting workforces and patients, drug testing and more.

All physicians should be strongly encouraged to co-prescribe naloxone to any patients receiving opioids (and more so for those getting opioids and benzodiazepines).

Static Up
157
Featured Stories